HZX-02-059
HZX-02-059 is a potent methuosis inducer and dual-target PIKfyve/tubulin inhibitor with anticancer activity. Methuosis mainly disrupts the balance of endocytosis and exocytosis, forming a large number of vesicles and inducing cell death. HZX-02-059 also induces cell vacuolization, promotes apoptosis, downregulates the p53 pathway, inhibits PI3K/AKT phosphorylation, and inhibits c-Myc and NF-κB transcription[1][2].
Product Specifications
CAS Number
2240205-30-3
Product Name Alternative
Methuosis inducer 1
UNSPSC
12352005
Target
Others
Type
Reference compound
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Methuosis_inducer_1.html
Purity
99.40
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; adjust pH to 3 with HCl; heat to 60°C)
Smiles
CC(C=CC(NC(C1=CC(C(F)(F)F)=CC=C1)=O)=C2)=C2NC3=CC(C4=CN=CC=C4)=NC5=C3C=CN5
Molecular Formula
C27H20F3N5O
Molecular Weight
487.48
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
![S-7,8-Difluoro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine Hydrogen Sulfate (Levofloxacin Impurity)](https://cdn.genprice.uk/genprice/uk/genprice5.webp)
S-7,8-Difluoro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine Hydrogen Sulfate (Levofloxacin Impurity)
S-7,8-Difluoro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine Hydrogen Sulfate (Levofloxacin Impurity)